In accordance with 37 C.F.R. §1.121, please substitute for original claims 3 and 5, the following rewritten versions of the same claims, as amended. The changes are shown explicitly in the attached "Version with Markings to Show Changes Made."

- 12
- 3. (Amended) The method according to claim 14, wherein the primary design antibody comprises CDRs of an antibody of a first animal species, and FRs of an antibody of a second animal species and having artificial amino acid residues that do not occur in nature.
- /3
- 5. (Amended) The method according to claim 14, wherein the artificial amino acid residues are ones occurring in the FRs of non-human antibody.
- 14. (New) A method for preparing a humanized antibody, wherein a framework region ("FR") in the humanized antibody is a FR naturally occurring in human antibodies, comprising the steps of:
- (1) Obtaining a primary design antibody which is humanized by a grafting of a complementarity determining region ("CDR") and which is substituted in one or more amino acid residues of the FR with artificial amino acids that do not occur in nature;
- 14
- (2) conducting a homology search using a database of amino acid sequences of FRs naturally occurring in human antibodies ("natural FRs") in comparison with a FR sequence of the primary design antibody;
- (3) preparing a list of amino acid sequences of the natural FRs having a high homology with the FR sequence in the primary design antibody;
- (4) selecting, from the list of step (3), a natural FR which contains a sequence that matches amino acids sequences substituted in step (1), and comprises an amino acid sequence that is the same as or has a high homology with the FR sequence of the primary design antibody;
- (5) if the FR sequence of the primary design antibody has one or more amino acids that are different from amino acids of the natural FR selected in step (4),

Atty. Dkt. No. 053466/0274

replacing said different amino acids in the FR sequence of the primary design antibody with corresponding amino acids in the natural FR;



- (6) constructing an expression vector expressing an amino acid sequence of the antibody obtained via steps (1) to (5);
- (7) culturing cells comprising an expression vector constructed in step (6); and
- (8) recovering the humanized antibody comprising the natural FR from the culture.